Journal Mobile Options
Table of Contents
Vol. 32, No. 1-2, 2009
Issue release date: February 2009
Onkologie 2009;32:44–46
Original Article · Originalarbeit

Sorafenib Induces Therapeutic Response in a Patient with Metastatic Collecting Duct Carcinoma of Kidney

Ansari J. · Fatima A. · Chaudhri S. · Bhatt R.I. · Wallace M. · James N.D.
University Hospital Birmingham NHS Trust, Birmingham, UK


Background: Collecting duct carcinoma (CDC) is a rare and aggressive variant of renal cell carcinoma (RCC), which has poor response to cytokine therapy and chemotherapy. Introduction of tyrosine kinase inhibitors (TKIs), in particular sorafenib and sunitinib, is changing the treatment paradigm for management of RCC. However, patients with CDC have been excluded from the majority of randomised trials involving the use of TKIs. Case Report: Our patient with metastatic CDC was treated with sorafenib, and demonstrated an excellent response, both clinically and radiologically. She continues on sorafenib treatment with minimal toxicity, and has demonstrated a progressionfree survival exceeding 13 months. Conclusions: This is the first reported case of a patient with CDC responding to sorafenib treatment. Therefore, the role of sorafenib in the management of metastatic CDC needs prospective evaluation.

 goto top of outline Author Contacts

Dr Jawaher Ansari, Specialist Registrar in Oncology, University Hospital Birmingham NHS Trust, Queen Elizabeth Hospital, Metchley Drive, Birmingham, B15 2TH, UK, Tel. +441912821734, Fax +441912563672,

 goto top of outline Article Information

Published online: January 19, 2009
Number of Print Pages : 3

 goto top of outline Publication Details

Onkologie (International Journal for Cancer Research and Treatment)

Vol. 32, No. 1-2, Year 2009 (Cover Date: February 2009)

Journal Editor: Schmoll H.-J. (Halle)
ISSN: 0378-584X (Print), eISSN: 1423-0240 (Online)

For additional information:

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.